63659-17-6

Basic information

• Product Name: 1-[4-(2-Hydroxyethyl)phenoxy]-2,3-epoxypropane
• Synonyms: 1-[4-(2-Hydroxyethyl)phenoxy]-2,3-epoxypropane;ZB-2;[[4-[2-(CyclopropylMethoxy)ethyl]phenoxy]Methyl]oxirane;2-[[4-[2-(cyclopropylMethoxy)ethyl]phenoxy]Methyl]oxirane;Betaxolol IMp. C (EP);Betaxolol IMp. C (EP)-d5;Betaxolol impurity C
• CAS NO: 63659-17-6
• Molecular Formula: C₁₅H₂₀O₃
• Molecular Weight: 194.22706
• Product Categories: Aromatics;Heterocycles;Impurities
• Mol File: 63659-17-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 358℃
• Flash Point: 121℃
• Appearance: /
• Density: 1.135
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: 1-[4-(2-Hydroxyethyl)phenoxy]-2,3-epoxypropane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(2-Hydroxyethyl)phenoxy]-2,3-epoxypropane(63659-17-6)
• EPA Substance Registry System: 1-[4-(2-Hydroxyethyl)phenoxy]-2,3-epoxypropane(63659-17-6)

Safety Data

• Hazardous Substances Data: 63659-17-6(Hazardous Substances Data)

Usage

Uses

[[4-[2-(Cyclopropylmethoxy)ethyl]phenoxy]methyl]oxirane (Betaxolol EP Impurity C) is Betaxolol (B328000) impurity.

Upstream product

• 63659-16-5 4-[2-(cyclopropylmethoxy)-ethyl]-phenol 
• 106-89-8 epichlorohydrin 
• 56441-69-1 2-<4-(phenylmethoxy)phenyl>acetic acid ethyl ester 
• 61439-59-6 2-(4-benzyloxyphenyl)ethanol 
• 63659-15-4 1-benzyloxy-4-(2-cyclopropylmethoxyethyl)benzene 
• 501-94-0 p-hydroxyphenethyl alcohol 
• 761449-63-2 1-(2-alyloxyethyl)-4-benzyloxybenzene 
• 128645-29-4 1-allyloxy-4-(2-cyclopropylmethoxyethyl)benzene 
• 3132-64-7 1,2-Epoxy-3-bromopropane 

Downstream Products

• 111794-56-0 6-<4-<3-phenoxy>-2-hydroxypropyl>amino>propionamido>phenyl>-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 133155-14-3 6-[4-[3-[3-(4-(2-Cyclopropylmethoxyethyl)phenoxy)-2-hydroxypropylamino]propylsulphonyl]phenyl]-4,5-dihydro-3(2H)-pyridazinone 
• 133155-06-3 6-[1-[2-[3-(4-(2-Cyclopropylmethoxy-ethyl)phenoxy)-2-hydroxypropylamino]ethyl]-2-hydroxy-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinone 
• 133155-03-0 6-[1-[2-[3-(4-(2-Cyclopropylmethoxy-ethyl)phenoxy)-2-hydroxypropylamino]ethyl]-2-methyl-benzimidazol-5-yl]-4,5-dihydro-3(2H)-pyridazinone 
• 133154-74-2 6-[3-[3-[3-(4-(2-Cyclopropylmethoxy-ethyl)phenoxy)-2-hydroxypropylamino]propoxy]phenyl]-4,5-dihydro-3(2H)-pyridazinone 
• 133154-71-9 6-[3-[2-[3-(4-(2-Cyclopropylmethoxy-ethyl)phenoxy)-2-hydroxypropylamino]ethoxy]phenyl]-4,5-dihydro-3(2H)-pyridazinone 
• 133154-53-7 6-[4-[3-[3-(4-(2-Cyclopropylmethoxy-ethyl)phenoxy)-2-hydroxypropylamino]propoxy]-3-chloro-phenyl]-4,5-dihydro-3(2H)-pyridazinone 
• 133154-65-1 6-[4-[2-[3-(4-(2-cyclopropylmethoxy-ethyl)phenoxy)-2-hydroxy-propylamino]ethoxy]phenyl]-4,5-dihydro-3(2H)-pyridazinone 
• 133177-58-9 6-[4-[2-[3-(4-(2-cyclopropylmethoxy-ethyl)phenoxy)-2-hydroxy-propylamino]ethoxy]-3-methyl-phenyl]-4,5-dihydro-3(2H)-pyridazinone 
• 133155-11-0 6-[1-[2-[3-(4-(2-Cyclopropylmethoxy-ethyl)phenoxy)-2-hydroxypropylamino]ethyl]benzimidazol-5-yl]-3(2H)-pyridazinone 

Relevant articles and documents

PROCESS FOR PREPARATION OF PHENOXYPROPANOL AMINES

The present invention describes an improved method for the preparation of l-[4-{2- (cyclopropylmethoxy)ethyl}phenoxy]-3-[(1-methylethyl)amino]-2-propanol of Formula-(I) and its pharmaceutically acceptable salt, which comprises reacting 4 - [ 2 — (Cyclopropylmethoxy) ethyl] phenol with epichlorohydrin in presence of mild base and polar protic solvent to isolate 1 - {4 - [2 - (cyclopropylmethoxy)ethyl] - phenoxy} - 2, 3 - epoxy propane, which is further reacted with isopropyl amine to get betaxolol formula (I).

Process for the selective alkylation of betaxolol intermediates

The present invention relates to a process for the selective alkylation of intermediates of betaxolol.

Design and synthesis of a series of combined vasodilator/β-adrenoceptor antagonists based on 6-arylpyridazinones

A series of new 6-[4-[[(aryloxy)acyl]amino]phenyl]-4,5-dihydropyridazinones have been synthesized and evaluated as combined vasodilator/β-adrenoceptor antagonists and potential antihypertensive agents. Many of the early compounds displayed an unacceptably high level of intrinsic sympathomimetic activity (ISA) and a relatively short duration of action. Disubstitution in the 2,3-positions or in the 4-position of the aryloxy ring gave compounds with low ISA levels and, in some instances, improved duration of action. All of the compounds were vasodilators, but the 5-methylpyridazinone derivatives showed consistently greater antihypertensive activity than their 5-H lower homologues. Further detailed pharmacological investigations led to the selection of 6-[4-[3-[[2-hydroxy-3-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]propyl]amino ]propionamido]phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone (4t) (SK&F 95018) as a development candidate.